Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Binodenoson. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 13/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.98 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Binodenoson SCHEMBL10089218 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL13259764 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL8932230 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL8922719 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL724956 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL940135 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL23898649 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL12877884 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL29379829 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL9346051 | 0.99 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130136693-A1 | Crystal Forms of 2--Adenosine | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC (US) | 2013-05-30 | — | — | US | claimed |
| US-20110044904-A1 | CRYSTAL FORMS OF 2--ADENOSINE | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2011-02-24 | — | — | US | claimed |
| EP-2257162-A2 | CRYSTAL FORMS OF 2-{2-Ý(CYCLOHEXYL)METHYLENE¨HYDRAZINO}ADENOSINE | King Pharmaceuticals Research and Development Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2009108829-A2 | CRYSTAL FORMS OF 2-{2-[(CYCLOHEXYL)METHYLENE]HYDRAZINO}ADENOSINE | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-09-03 | — | — | WO | claimed |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | NORTHEASTERN UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| US-8883500-B2 | Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy | NORTHEASTERN UNIVERSITY (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | SITKOVSKY MICHAIL V (US) | 2013-12-05 | — | — | US | disclosed |
| CN-103415286-A | Compounds and methods for treating pain | AKRON MOLECULES GMBH | 2013-11-27 | — | — | CN | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| US-20070213296-A1 | Compositions and methods for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| WO-2007089617-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH | COMBINATORX, INCORPORATED (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007056457-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060159621-A1 | Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006076698-A1 | METHOD OF DETECTING MYOCARDIAL DYSFUNCTION IN PATIENTS HAVING A HISTORY OF ASTHMA OR BRONCHOSPASM | KING PHARMACEUTICALS RESERCH & DEVELOPMENT, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-0983768-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Nippon Shinyaku Co., Ltd. (JP) | 2000-03-08 | — | — | EP | disclosed |
| US-5278150-A | Vasodilation | WHITBY RESEARCH, INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0567094-A2 | Hydrazoadenosines | Discovery Therapeutics, Inc. (US) | 1993-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136693-A1 | Crystal Forms of 2--Adenosine | ADORA2A, NT5C2, ADORA3 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 5/4885 |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | ADORA2A 126/4885ADORA1 348/4885ADORA2B 48/4885 |
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 5/4885 |
| US-20060159621-A1 | Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm | TNNI3, BDKRB2, BDKRB1 | ADORA2A 293/4885ADORA1 362/4885ADORA2B 60/4885 |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 5/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | ADORA2A 126/4885ADORA1 348/4885ADORA2B 48/4885 |
| US-20110044904-A1 | CRYSTAL FORMS OF 2--ADENOSINE | ADORA2A, NT5C2, ADORA3 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 5/4885 |
| US-20070213296-A1 | Compositions and methods for the treatment of immunoinflammatory disorders | MPO, IL5, SERPINA6 | ADORA2A 12/4885ADORA1 78/4885ADORA2B 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.